Sulfonylureas (SU)

DRUG4 trials

Sponsors

Eli Lilly and Company, Janssen Research & Development, LLC, Samsung Medical Center

Conditions

COPD (Chronic Obstructive Pulmonary Disease)Cardiovascular DiseasesDiabetes Mellitus, Type 2Lung Cancer (Diagnosis)Type 2 DiabetesType 2 Diabetes Mellitus

Phase 3

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

CompletedNCT01468181

Eli Lilly and CompanyType 2 Diabetes Mellitus

Start: 2011-11-30End: 2013-12-31Updated: 2015-01-29

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

CompletedNCT01584232

Eli Lilly and CompanyType 2 Diabetes Mellitus

Start: 2012-04-30End: 2013-07-31Updated: 2014-10-20

Unknown Phase

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

CompletedNCT03492580

Janssen Research & Development, LLCCardiovascular Diseases, Diabetes Mellitus, Type 2

Start: 2018-02-22End: 2018-06-25Updated: 2025-06-25

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

CompletedNCT07332156

Samsung Medical CenterCOPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis), Type 2 Diabetes

Start: 2009-01-01End: 2023-12-31Updated: 2026-01-14

Related Papers

The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.

2018-02-0710 citations

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.

2017-06-1210 citations